Cargando…
Computational Drug Repurposing for Alzheimer’s Disease Using Risk Genes From GWAS and Single-Cell RNA Sequencing Studies
Background: Traditional therapeutics targeting Alzheimer’s disease (AD)-related subpathologies have so far proved ineffective. Drug repurposing, a more effective strategy that aims to find new indications for existing drugs against other diseases, offers benefits in AD drug development. In this stud...
Autores principales: | Xu, Yun, Kong, Jiming, Hu, Pingzhao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8277916/ https://www.ncbi.nlm.nih.gov/pubmed/34276354 http://dx.doi.org/10.3389/fphar.2021.617537 |
Ejemplares similares
-
Computational drug repurposing for inflammatory bowel disease using genetic information
por: Grenier, Liam, et al.
Publicado: (2019) -
Drug repurposing for Alzheimer’s disease from 2012–2022—a 10-year literature review
por: Grabowska, Monika E., et al.
Publicado: (2023) -
From GWAS to drug screening: repurposing antipsychotics for glioblastoma
por: Lin, Wei-Zhi, et al.
Publicado: (2022) -
Expert-Augmented Computational Drug Repurposing Identified Baricitinib as a Treatment for COVID-19
por: Smith, Daniel P., et al.
Publicado: (2021) -
On the Integration of In Silico Drug Design Methods for Drug Repurposing
por: March-Vila, Eric, et al.
Publicado: (2017)